Dhingra et al. reported that LIFR expression in patient tumors was significantly correlated with the presence of estrogen receptor [85], and LIFR expression and function are typically the highest in ER+ breast cancer cell lines [73], although ER− SUM159 cells also possess an active LIFR capable of inducing downstream signals in response to the ligand [24,73]. The gene discussed is LIFR; the disease is breast cancer.